CARMIL1

Across TCGA pan-cancer cohorts, CARMIL1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated CARMIL1 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CARMIL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CARMIL1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, BLCA, and READ are the cancer types where CARMIL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.093	0.542	<.001	36	view →
BLCA	DFS	Median	III,IV	0.153	0.551	<.001	27	view →
READ	DFS	Median	All	0.112	0.845	.001	12	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	11	view →
UCEC	DFS	Median	All	0.911	0.608	.010	8	view →
COAD	OS	Median	II,III,IV	0.569	0.866	.031	7	view →
SARC	DFS	Median	All	0.103	0.613	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	All	0.119	0.539	.041	3	view →
LIHC	OS	Median	All	0.144	0.704	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

CARMIL1–OV (DFS)

Open the OV breakdown →